These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

459 related items for PubMed ID: 17292473

  • 1. Morphometric effects of long-term exposure to latanoprost.
    Cracknell KP, Grierson I, Hogg P.
    Ophthalmology; 2007 May; 114(5):938-48. PubMed ID: 17292473
    [Abstract] [Full Text] [Related]

  • 2. Latanoprost-induced iris darkening: a morphometric study of human peripheral iridectomies.
    Cracknell KP, Grierson I, Hogg P, Appleton P, Pfeiffer N.
    Exp Eye Res; 2003 Dec; 77(6):721-30. PubMed ID: 14609560
    [Abstract] [Full Text] [Related]

  • 3. Iris morphology.
    Teus MA, Arranz-Marquez E.
    Ophthalmology; 2008 Feb; 115(2):418-9; author reply 419-20. PubMed ID: 18243921
    [No Abstract] [Full Text] [Related]

  • 4. Analysis of irises with a latanoprost-induced change in iris color.
    Arranz-Marquez E, Teus MA, Saornil MA, Mendez MC, Gil R.
    Am J Ophthalmol; 2004 Oct; 138(4):625-30. PubMed ID: 15488791
    [Abstract] [Full Text] [Related]

  • 5. Monte Carlo simulation of latanoprost induced iris darkening.
    Cracknell KP, Farnell DJ, Grierson I.
    Comput Methods Programs Biomed; 2007 Aug; 87(2):93-103. PubMed ID: 17576020
    [Abstract] [Full Text] [Related]

  • 6. Fine structural evaluation of the iris after unilateral treatment with latanoprost in patients undergoing bilateral trabeculectomy (the Mainz II study).
    Pfeiffer N, Grierson I, Goldsmith H, Appleton P, Hochgesand D, Winkgen A.
    Arch Ophthalmol; 2003 Jan; 121(1):23-31. PubMed ID: 12523881
    [Abstract] [Full Text] [Related]

  • 7. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients.
    Albert DM, Gangnon RE, Zimbric ML, Damico CM, Fisher MR, Gleiser J, Grossniklaus HE, Green WR.
    Arch Ophthalmol; 2004 Nov; 122(11):1680-5. PubMed ID: 15534130
    [Abstract] [Full Text] [Related]

  • 8. A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides.
    Albert DM, Gangnon RE, Grossniklaus HE, Green WR, Darjatmoko S, Kulkarni AD.
    Arch Ophthalmol; 2008 May; 126(5):626-31. PubMed ID: 18474771
    [Abstract] [Full Text] [Related]

  • 9. Histology and fine structure of the iris and outflow system following latanoprost therapy.
    Grierson I, Pfeiffer N, Cracknell KP, Appleton P.
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S176-84. PubMed ID: 12204715
    [Abstract] [Full Text] [Related]

  • 10. Latanoprost and pigmentation.
    Grierson I, Jonsson M, Cracknell K.
    Jpn J Ophthalmol; 2004 Aug; 48(6):602-12. PubMed ID: 15592791
    [Abstract] [Full Text] [Related]

  • 11. Melanin in the trabecular meshwork is associated with age, POAG but not Latanoprost treatment. A masked morphometric study.
    Cracknell KP, Grierson I, Hogg P, Majekodunmi AA, Watson P, Marmion V.
    Exp Eye Res; 2006 Jun; 82(6):986-93. PubMed ID: 16297910
    [Abstract] [Full Text] [Related]

  • 12. The color of the human eye: a review of morphologic correlates and of some conditions that affect iridial pigmentation.
    Imesch PD, Wallow IH, Albert DM.
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S117-23. PubMed ID: 9154287
    [Abstract] [Full Text] [Related]

  • 13. Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes.
    Chou SY, Chou CK, Kuang TM, Hsu WM.
    Eye (Lond); 2005 Jul; 19(7):784-7. PubMed ID: 15359238
    [Abstract] [Full Text] [Related]

  • 14. Characterization of melanin in human iridal and choroidal melanocytes from eyes with various colored irides.
    Wakamatsu K, Hu DN, McCormick SA, Ito S.
    Pigment Cell Melanoma Res; 2008 Feb; 21(1):97-105. PubMed ID: 18353148
    [Abstract] [Full Text] [Related]

  • 15. Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue.
    Lindquist NG, Larsson BS, Stjernschantz J.
    Exp Eye Res; 1999 Oct; 69(4):431-6. PubMed ID: 10504276
    [Abstract] [Full Text] [Related]

  • 16. Latanoprost-induced iris color darkening: a case report with long-term follow-up.
    Camras CB, Neely DG, Weiss EL.
    J Glaucoma; 2000 Feb; 9(1):95-8. PubMed ID: 10708238
    [Abstract] [Full Text] [Related]

  • 17. Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report.
    Tsai JC, Sivak-Callcott JA, Haik BG, Zhang J, McLean IW.
    J Glaucoma; 2001 Oct; 10(5):411-3. PubMed ID: 11711840
    [Abstract] [Full Text] [Related]

  • 18. alpha-Methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro.
    Drago F, Marino A, La Manna C.
    Exp Eye Res; 1999 Jan; 68(1):85-90. PubMed ID: 9986745
    [Abstract] [Full Text] [Related]

  • 19. Latanoprost-induced changes in the iris and trabeculum: an electron-microscopic morphological study.
    Yildirim N, Sahin A, Kara S, Baycu C.
    Int Ophthalmol; 2010 Feb; 30(1):93-7. PubMed ID: 19139827
    [Abstract] [Full Text] [Related]

  • 20. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change.
    Grierson I, Lee WR, Albert DM.
    Arch Ophthalmol; 1999 Mar; 117(3):394-6. PubMed ID: 10088822
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.